A university spin-out company that is developing a highly accurate fingerprint identification technology has raised £15,000 from business angel investors.
Fresh off its recent Bioentrepreneur of the Year Award win, London biopharmaceutical company Lipoxen Plc announced it has raised £2.6m in new funding.
Cambridge Antibody Technology (CAT) and Scil Proteins GmbH have signed a cross-licence agreement, the two companies have announced.
Dr. Nicholas Miller, of Beremans Limited (www.beremans.com), and Ingelise Saunders, of ACE Biosciences AS (www.acebiosciences.com), discuss the growing need for and potential value in the development of a vaccine for Travellers’ Diarrhoea
Stop whingeing about interest rates and start investing in the UK’s world leading technical innovators – it will be the willingness and ability to leverage British Intellectual Property that will determine economic success in the long term, argues Matthew Walls, chief executive officer of Oxford BioSignals.
